Interim Results from the CATNON trial (EORTC study 260-53-22054) of treatment with Concurrent and Adjuvant Temozolomide for 1p/19q non-co-deleted anaplastic glioma: A phase 3, randomized, open-label intergroup study
Lancet 390:1645-1653, Van Den Bent, M.J.,et al, 2017
Maintenance Therapy with Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma
JAMA 314:2535-2543,2511, Stupp, R.,et al, 2015
Malignant Gliomas in Adults
NEJM 359:492-507, Wen,P.Y. &Kesari,S., 2008
Outcome in Adult Low-Grade Glioma: The Impact of Prognostic Factors and Treatment
Neurol 69:1366-1373, Schiff,D.,et al, 2007
Gliomatosis Cerebri: Molecular Pathology and Clinical Course
Ann Neurol 52:390-399,389, Herrlinger,U.,et al, 2002
Long-Term Outcome of Low-Grade Oligodendroglioma and Mixed Glioma
Neurol 54:1442-1448,1402, Olson,J.D.,et al, 2000
Brain Tumors in the Elderly
Arch Neurol 55:922-928, Lowry,J.K.,et al, 1998
Central Nervous System Relapse in Non-Hodgkin Lymphoma
Arch Neurol 54:854-859, Bollen,E.L.E.M.,et al, 1997
Radiotherapy for Malignant Glioma
BMJ 313:1500-1501, Gregor,A.,et al, 1996
Central Nervous System Germinomas, A Review
Arch Neurol 48:652-657, Horowitz,M.B.&Hall,W.A., 1991
Cerebral Reticulum Cell Sarcoma
Arch Neurol 36:727, DeCoul,A.A.W.,et al, 1979